Advertisement

Ergebnisse und Möglichkeiten der Behandlung beim kleinzelligen Bronchialkarzinom

  • N. Niederle
Conference paper

Zusammenfassung

Das kleinzellige Bronchialkarzinom stellt eine recht gut definierte eigenständige Krankheitsentität dar. Es unterscheidet sich von den nichtkleinzelligen Bronchialkarzinomen durch feingewebliche, ultrastrukturelle, endokrine, zytogenetische, zellkinetische und klinische Befunde (Azzopardi, 1959; Bensch et al., 1968; Bondy u. Gilby, 1982; Campobasso et al., 1974; Gropp et al., 1980; Hattorf et al., 1972; Hirsch et al., 1982; Mountain, 1973; Richardson et al., 1978; Watson und Berg, 1962; Whang-Peng et al., 1982, WHO, 1983). Die röntgenologisch bestimmbare kurze Tumorverdopplungszeit (im Mittel 20–50 Tage) und die mittels 3H-Thymidin-Markierung gemessene hohe Wachstumsfraktion manifestieren sich klinisch in dem schnellen Tumorwachstum, einer in der Regel nur kurzen klinischen Symptomatik von unter 3 Monaten und der frühzeitigen Disseminationstendenz (Auerbach et al., 1975; Brigham et al. 1978; Chahinian, 1972; Hansen et al., 1978; Kato et al., 1969; Matthews et al., 1973; Meyer, 1973; Muggia u. Chervu, 1974; Muggia et al., 1974; Pettengill et al., 1980; Salazar et al., 1976; Straus, 1974; Weiss et al, 1970; Weiss, 1974).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abeloff MD, Ettinger DS, Order SE, Khouri N, Mellits ED, Dorschel NT, Baumgardner R (1981) Intensive induction chemotherapy in 54 patients with small cell carcinoma of the lung. Cancer Treat Rep 65: 639–646PubMedGoogle Scholar
  2. Aisner K, Whitacre M, van Echo DA, Wiernik PH (1982) Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. Cancer Treat Rep 66: 221–230PubMedGoogle Scholar
  3. Alberto P, Brunner KW, Martz G, Obrecht J-P, Sonntag RW (1976) Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristine. Cancer 38: 2208–2216PubMedCrossRefGoogle Scholar
  4. Alexander M, Glatstein EJ, Gordon DS, Daniels JR (1977) Combined modality treatment for oat cell carcinoma of the lung: a randomized trial. Cancer Treat Rep 61: 1–6PubMedGoogle Scholar
  5. Allan SG, Gregor A, Cornbleet MA, Leonard RCF, Smyth JF, Grant IWB, Crompton GK (1984) Phase II trial of vindesine and VP 16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer. Cancer Chemother Pharmacol 13: 106–108PubMedCrossRefGoogle Scholar
  6. Anderson G, Bowyer F, Williams L (1981) Oral VP-16-213 in advanced bronchogenic carcinoma and toxic effects when combined with methotrexate. Thorax 35: 462–464CrossRefGoogle Scholar
  7. Aroney RS, Bell DR, Chan WK, Dalley DN, Levi JA (1982) Alternating non-cross-resistant combination chemotherapy for small cell anaplastic carcinoma of the lung. Cancer 49: 2449–2454PubMedCrossRefGoogle Scholar
  8. Auerbach O, Garflnkel L, Parks VR (1975) Histologic type of lung cancer in relation to smoking habits, year of diagnosis and sites of metastases. Chest 67: 382–387PubMedCrossRefGoogle Scholar
  9. Azzopardi JG (1959) Oat-cell carcinoma of the bronchus. J Path Bact 78: 513–519PubMedCrossRefGoogle Scholar
  10. Baglan RJ, Marks JE (1981) Comparison of symptomatic and prophylactic irradiation of brain metastases from oat cell carcinoma of the lung. Cancer 47: 41–45PubMedCrossRefGoogle Scholar
  11. Bakker W; Nijhuis-Heddes JMA, van Oosterom AT, Noordijk EM, Hermans J, Dijkman JH (1984) Combined modality treatment of short duration in small cell lung cancer. Eur J Cancer Clin Oncol 20: 1033–1037PubMedCrossRefGoogle Scholar
  12. Ball ED, Graziano RF, Pettengill OS, Sorenson GD, Fanger NW (1984) Monoclonal antibodies reactive with small cell carcinoma of the lung. J Natl Cancer Inst 72: 593–598PubMedGoogle Scholar
  13. Batist G, Ihde DC, Zabell A, Lichter AS, Veach SR, Cohen MH, Carney DN, Bunn PA (1983) Small cell carcinoma of the lung: reinduction therapy after late relapse. Ann Intern Med 98: 472–474PubMedGoogle Scholar
  14. Baudrexl A, Wilde I sen, Eule H, Dippmann A, Haenselt V, Baudrexl R, Bieselt R, Brethner J, Haupt R, Wilde I jun (1984) Die chirurgische Behandlung des kleinzelligen Bronchialkarzinoms. Arch Geschwulstforsch 54: 61–67Google Scholar
  15. Becker H, Borst HG, Brieler HS, Dahm P, Dalichau H, Donhöfer A, Hegemann G, Junginger TH, Kessler E, Kümmerle F, Mühe E, Pichlmaier H, Reidemeister JC, Reusch G, Satter P, Savic B, Sommerwerck D, Schotte JF, Schwaiger R, Stöhr U, Strothmann A, Täger B, Timm D, Ungeheuer E, Viereck R, Wache H, Wassner UJ, Zierott G (1976) Ergebnisse der operativen Behandlung des Bronchialkarzinoms. Dtsch Med Wochenschr 101: 1553–1557CrossRefGoogle Scholar
  16. Bensch KG, Corrin B, Pariente R, Spencer H (1968) Oat-cell carcinoma of the lung. Its origin and relationship to bronchial carcinoid. Cancer 22: 1163–1172Google Scholar
  17. Bergsagel DE, Jenkin RDT, Pringle JF, White DM, Fetterly JCM, Klaassen DJ, McDermot RSR (1972) Lung cancer: clinical trial of radiotherapy alone vs. radiotherapy plus cyclophosphamide. Cancer 30: 621–627PubMedCrossRefGoogle Scholar
  18. Bhuchar VK, Lanzotti VJ (1972) High-dose cisplatin for lung cancer. Cancer Treat Rep 66: 375–376Google Scholar
  19. Bleehen NM, Jones DH, Slater AJ (1982) High dose human lymphoblastoid interferon in the treatment of small cell carcinoma of bronchus. III. World Conference on Lung Cancer, Tokyo 1982; Abstracts, S. 161Google Scholar
  20. Bleehen NM, Bunn PA, Cox JD, Dombernowsky P, Fox RM, Host H, Joss R, White JE, Wittes RE (1983) Role of radiation therapy in small cell anaplastic carcinoma of the lung. Cancer Treat Rep 67: 11–19PubMedGoogle Scholar
  21. Bohndorf W, Richter E (1979) Ergebnisse nach 2-Serien-Bestrahlung des Bronchialkarzinoms. Strahlentherapie 155: 596–600PubMedGoogle Scholar
  22. Bondy PK, Gilby ED (1982) Endocrine function in small cell undifferentiated carcinoma of the lung. Cancer 50: 2147–2153PubMedCrossRefGoogle Scholar
  23. Brigham BA, Bunn PA, Minna JD, Cohen MH, Ihde DC, Shackney SE (1978) Growth rates of small cell bronchogenic carcinomas. Cancer 42: 2880–2886PubMedCrossRefGoogle Scholar
  24. Broder LE, Cohen MH, Selawry OS (1977) Treatment of bronchogenic carcinoma. II. Small cell. Cancer Treat Rev 4: 219–260PubMedCrossRefGoogle Scholar
  25. Brower M, Ihde DC, Johnston-Early A, Bunn PA Jr, Cohen MH, Carney DN, Makuch RW, Matthews MJ, Radice PA, Minna JD (1983) Treatment of extensive stage small cell bronchogenic carcinoma. Effects of variation in intensity of induction chemotherapy. Am J Med 75: 993–1000PubMedCrossRefGoogle Scholar
  26. Bunting N, Bonomi P, O’Reilly W, Vogl S, Creech R, Ruckdeschel J, Stolbach L, Ettinger D (1984) Prognostic factors in patients with small cell bronchogenic carcinoma treated on an ECOG phase II trial. Proc Am Soc Clin Oncol 3: 228 (C-891)Google Scholar
  27. Burdon JGW, Sinclair RA, Henderson MM (1979) Small cell carcinoma of the lung. Prognosis in relation to histologic subtype. Chest 76: 302–304PubMedCrossRefGoogle Scholar
  28. Burgess RE, Burgess VF, Dibella NJ (1979) Brain metastases in small cell carcinoma of the lung. J Am Med Assoc 242: 2084–2086CrossRefGoogle Scholar
  29. Byhardt RW, Cox JD (1983) Is chest radiotherapy necessary in any or all patients with small cell carcinoma of the lung? Cancer Treat Rep 67: 209–215Google Scholar
  30. Byhardt RW, Libnoch JA, Cox JD, Holoye PY, Kun L, Komaki R, Clowry L (1981) Local control of intrathoracic disease with chemotherapy and role of prophylactic cranial irradiation in small-cell carcinoma of the lung. Cancer 47: 2239–2246PubMedCrossRefGoogle Scholar
  31. Campobasso O, Invernizzi B, Musso M, Berrino F (1974) Survival rates of lung cancer according to histological type. Br J Cancer 29: 240–246PubMedCrossRefGoogle Scholar
  32. Carney DN, Marangos PJ, Ihde DC, Bunn PH Jr, Cohen MH, Minna JD, Gazdar AF (1982) Serum neuron-specific enolase: a marker for disease extent and response to therapy of small- cell lung cancer. Lancet 1: 583–585PubMedCrossRefGoogle Scholar
  33. Carney DN, Broder L, Edelstein M, Gazdar AF, Hansen M, Havemann K, Matthews MJ, Sorenson GD, Videlov L (1983) Experimental studies of the biology of human small cell lung cancer. Cancer Treat Rep 67: 27–35PubMedGoogle Scholar
  34. Carney DN, Gazdar AF, Nau M, Little, C, Minna JD (1984) Two distinct classes of tumor cells cultured from patients with small cell lung cancer. Proc Am Soc Clin Oncol 3: 218 (C-851)Google Scholar
  35. Carr DT, Childs DS Jr, Lee RE (1972) Radiotherapy plus 5-FU compared to radiotherapy alone for inoperable and unresectable bronchogenic carcinoma. Cancer 29: 375–380PubMedCrossRefGoogle Scholar
  36. Catane R, Lichter A, Lee YJ, Brereton HD, Schwade JD, Glatstein E (1981) Small cell lung cancer: analysis of treatment factors contributing to prolonged survival. Cancer 48: 1936–1943PubMedCrossRefGoogle Scholar
  37. Cate CC, Douple EB, Andrews KM, Pettengill OS, Curphey TJ, Sorenson GD, Maurer LH (1984) Calcitonin as an indicator of the response of human small cell carcinoma of the lung cells to drugs and radiation. Cancer Res 44: 949–954PubMedGoogle Scholar
  38. Cavalli F, Sonntag RW, Jungi F, Senn HJ, Brunner KW (1978) VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 62: 473–475PubMedGoogle Scholar
  39. Cavalli F, Goldhirsch A, Siegenthaler P, Kaplan S, Beer M (1980) Phase-II study with cisdichlo- rodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma. Eur J Cancer 16: 617–621PubMedGoogle Scholar
  40. Chahinian P (1972) Relationship between tumor doubling time and anatomoclinical features in 50 measurable pulmonary cancers. Chest 61: 340–345PubMedCrossRefGoogle Scholar
  41. Chahinian AP, Ware JH, Zimmer B, Comis RL, Perry MC, Hirsh Y, Skarin AT, Raich PC, Weiss RB, Carey RW (1984) Evaluation of anticoagulation with warfarin and of alternating chemotherapy in extensive small cell cancer of the lung. Proc Am Soc Clin Oncol 3: 225 (C- 879)Google Scholar
  42. Chak LY, Daniels JR, Sikic BI, Torti FM, Lockbaum P, Carter SK (1982) Patterns of failure in small cell carcinoma of the lung. Cancer 50: 1857–1863PubMedCrossRefGoogle Scholar
  43. Choi CH, Carey RW (1976) Small cell anaplastic carcinoma of lung. Reappraisal of current management. Cancer 37: 2651–2657PubMedCrossRefGoogle Scholar
  44. Cohen MH (1983) Is thoracic radiation therapy necessary for patients with limited-stage small cell lung cancer? No. Cancer Treat Rep 67: 217–221Google Scholar
  45. Cohen MH, Broder LE, Fossieck BE, Ihde DC, Minna JD (1977) Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma. Cancer Treat Rep 61: 489–490PubMedGoogle Scholar
  46. Cohen MH, Ihde DC, Bunn PA Jr, Fossieck BE Jr, Matthews MJ, Shackney SE, Johnston-Early A, Makuch R, Minna JD (1979) Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep 63: 163–170PubMedGoogle Scholar
  47. Comis R, Meyer J, Ginsberg S, Poiesz B, DiFino S, Gullo J (1984) The impact of TNM stage on results with chemotherapy and adjuvant surgery in small cell lung cancer Proc Am Soc Clin Oncol 3:226 (C-884)Google Scholar
  48. Cornbleet M, Gregor A, Allan S, Leonard R, Smyth J (1984) High dose melphalan as consolidation therapy for good prognosis patients with small cell carcinoma of bronchus. Proc Am Soc Clin Oncol 3: 210 (C-820)Google Scholar
  49. Costanzi J J, Gagliano R, Loukas D, Panettiere FJ, Hokanson J A (1978) Ifosfamide in the treatment of recurrent or disseminated lung cancer. A phase II study of two dose schedules. Cancer 41: 1715–1719PubMedCrossRefGoogle Scholar
  50. Cowan B, Poiesz B, Carney D, Catino J, Bradley E, Issel B, Comis R (1984) Small cell lung cancer cell cultures derived from primary tumors following chemotherapy response. Proc Am Soc Clin Oncol 3: 198 (C-773)Google Scholar
  51. Cox JD, Yesner R, Mietlowski W, Petrovich Z (1979) Influence of cell type on failure pattern after irradiation for locally advanced carcinoma of the lung. Cancer 44: 94–98PubMedCrossRefGoogle Scholar
  52. Cox JD, Komaki R, Eisert DR (1980) Irradiation for inoperable carcinoma of the lung and high performance status. J Am Med Assoc 244: 1931–1933CrossRefGoogle Scholar
  53. Craig J, Jackson D, Moody D, Pope E, Cruz J, Hopkins J, White D, Richards F, Muss H, Stuart J, Zekan P, Cooper M, Spurr C, Capizzi R, Atkins J, Powell B (1984) Prospective evaluation of changes in computerized cranial tomography in patients with small cell carcinoma treated with chemotherapy and cranial irradiation. Proc Am Soc Clin Oncol 3: 224 (C-875)Google Scholar
  54. Creech RH, Stanley K, Vogl SE, Ettinger DS, Bonomi PD, Salazar O (1982) Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). Cancer Treat Rep 66: 1417–1419PubMedGoogle Scholar
  55. Creech RH, Tritchler D, Ettinger DS, Ferraro J A, Ruckdeschel JC, Vogl SE, Woll J (1984) Phase II study of PALA, amsacrine, teniposide and zinostatin in small cell lung carcinoma (EST 2579). Cancer Treat Rep 68: 1183–1184PubMedGoogle Scholar
  56. Cuttitta F, Rosen S, Gazdar AF, Minna JD (1981) Monoclonal antibodies that demonstrate specificity for several types of human lung cancer. Proc Natl Acad Sci USA 78: 4591–4595PubMedCrossRefGoogle Scholar
  57. Daugaard G, Hansen HH, Rorth M (1984) Phase II study of vindesine, cisplatin and hexameth-ylmelamine (VCH) in small cell carcinoma of the lung. Cancer Treat Rep 68: 1179–1181PubMedGoogle Scholar
  58. DeJager R, Longeval E, Klastersky J (1980) High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium). Cancer Treat Rep 64: 1341–1346Google Scholar
  59. Dillman RO, Taetle R, Seagren S, Royston I, Koziol J, Mendelsohn J (1982) Extensive disease small cell carcinoma of the lung. Trial of non-cross resistant chemotherapy and consolidation radiotherapy. Cancer 49: 2003–2008PubMedCrossRefGoogle Scholar
  60. Dombernowsky P, Sorenson S, Aisner J, Hansen HH (1979) Cis-chlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma: a phase II study. Cancer Treat Rep 63: 534–545Google Scholar
  61. Eagan RT, Lee RE, Frytak S, Ingle JN, Creagan ET (1980) Combination chemotherapy with and without cis-diamminedichloroplatinum (II) plus thoracic radiation therapy for limited small cell lung cancer. Proc Am Assoc Cancer Res 21: 131 (523)Google Scholar
  62. Eagan RT, Frytak S, Nichols WC, Ingle JN, Creagan ET, Kvols LK (1981) Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancer. Cancer Treat Rep 65: 453–458PubMedGoogle Scholar
  63. Edmonson JH, Lagakos SW, Selawry OS, Perlia CP, Bennett JM, Muggia FM, Wampler G, Brodovsky HS, Horton J, Colsky J, Mansour EG, Creech R, Stolbach L, Greenspan EM, Levitt M, Israel L, Ezdinli EZ, Carbone PP (1976) Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 60: 925–932PubMedGoogle Scholar
  64. Einhorn LH, Williams SD, Loehrer PJ (1984) Platinum + VP-16 chemotherapy for refractory small cell lung cancer. Proc Am Assoc Cancer Res 25: 174 (689)Google Scholar
  65. Emami B, Munzenrider JE, Lee DJ, Rene JB (1979) Radical radiation therapy of advanced lung cancer. Evaluation of prognostic factors and results of continuous and split course treatment. Cancer 44: 446–456PubMedCrossRefGoogle Scholar
  66. Ernst P, Olesen BK, Nissen MH, Hokland P, Justesen J, Hansen HH (1984) In vivo effect of recombinant interferon alpha (IFN) in patients with lung cancer. Proc Am Soc Clin Oncol 3: 66 (C-258)Google Scholar
  67. Evans WK, Osoba D, Feld R, Shepherd FA, Bazos M, DeBoer G (1984) VP-16 and cisplatin for small cell lung cancer after failure of induction chemotherapy. Proc Am Soc Clin Oncol 3: 222 (C-868)CrossRefGoogle Scholar
  68. Eyben F von, Arwidi Ä, Mattsson W (1980) VP-16 213 in small cell carcinoma of the lung. In: Hansen HH, Dombernowsky P (eds): Abstracts II. World Conference on Lung Cancer. Excerpta medica, Amsterdam-Oxford, Princeton, p 227Google Scholar
  69. Farha P, Spitzer G, Valdivieso M, Dicke KA, Zander A, Dhingra HM, Minnhaar G, Vellekoop L, Verma DS, Umsawasdi T, Chiuten D (1983) High-dose chemotherapy and autologous bone marrow transplantation for the treatment of small cell lung carcinoma. Cancer 52: 1351–1355PubMedCrossRefGoogle Scholar
  70. Feld R, Evans WK, DeBoer G, Quirt IC, Shepherd FA, Yeoh JL, Pringle JF, Payne DG, Herman JG, Chamberlain D, Brown TC, Baker MA, Myers R, Blackstein ME, Pritchard KI (1984) Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol 2: 294–304PubMedGoogle Scholar
  71. Fox RM, Woods RL, Brodie GN, Tattersall MHN (1980) A randomized study: small cell anaplastic lung cancer treated by combination chemotherapy and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 6: 1083–1085PubMedCrossRefGoogle Scholar
  72. Fox W, Scadding JG (1973) Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet 2: 63–65PubMedCrossRefGoogle Scholar
  73. Freise G, Gabler A, Liebig S (1973) Bronchial carcinoma and long-term survival. Retrospective study of 433 patients who underwent resection. Thorax 33: 228–234CrossRefGoogle Scholar
  74. Gatzemeier U (1983) Mehrjährige Verlaufsbeobachtung und Ergebnisse nach Chemotherapie (ACO) des kleinzelligen Bronchialkarzinoms. Prax Klin Pneumol 37: 144–147PubMedGoogle Scholar
  75. Ginsberg RJ, Shepherd FA, Evans WK, Feld R, Cooper JD, Ilves R, Todd TRJ, Pearson FG, Waters PF, Baker MA (1983) Chemotherapy followed by adjuvant surgery in the treatment of limited small cell carcinoma (SCLC). 13th International Congress of Chemotherapy, Vienna. Proceedings, Vol 11, part 228, pp 14–18Google Scholar
  76. Glode LM, Robinson WA, Hartmann DW, Klein JJ, Thomas MR, Morton N (1982) Autologous bone marrow transplantation in the therapy of small cell carcinoma of the lung. Cancer Res 42: 4270–4275PubMedGoogle Scholar
  77. Goldhirsch A, Joss R, Sonntag RW, Brunner KW (1980) Vindesin, ein neues Zytostatikum aus der Reihe der Vinca-Alkaloide. Dtsch Med Wochenschr 105: 931–935PubMedCrossRefGoogle Scholar
  78. Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66: 439–449PubMedGoogle Scholar
  79. Goldsweig HG, Edgerton F, Redden SC, Takita H, DeLa Garza JG, Bisel HF (1982) Hexameth- ylmelamine as a single agent in the treatment of small-cell carcinoma of the lung. Am J Clin Oncol 5: 267–272PubMedCrossRefGoogle Scholar
  80. Greco FA, Einhorn LH, Hände KR, Oldham RK (1979 a) Phase II studies in resistant small cell lung cancer. Proc Am Assoc Cancer Res, Am Soc Clin Oncol 20: 28Google Scholar
  81. Greco FA, Richardson RL, Snell JD, Stroup SL, Oldham RK (1979 b) Small cell lung cancer. Complete remission and improved survival. Am J Med 66: 625–630Google Scholar
  82. Greschuchna D, Maaßen W (1980) The importance of histological classification and tumor staging for prognosis after resection of bronchial carcinoma. Thorac Cardiovasc Surg 28: 115–119PubMedCrossRefGoogle Scholar
  83. Gropp C, Havemann K, Scheuer A (1980) Ectopic hormones in lung cancer patients at diagnosis and during therapy. Cancer 46: 347–354PubMedCrossRefGoogle Scholar
  84. Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197: 461–463PubMedCrossRefGoogle Scholar
  85. Hansen HH, Dombernowsky P, Hirsch FR (1978) Staging procedures and prognostic features in small cell anaplastic bronchogenic carcinoma. Semin Oncol 5: 280–287PubMedGoogle Scholar
  86. Hansen HH, Dombernowsky P, Hansen HS, Rørth M (1979) Chemotherapy versus chemotherapy plus radiotherapy in regional small-cell carcinoma of the lung. A randomized trial. Proc Am Assoc Cancer Res, Am Soc Clin Oncol 20: 277 (1124)Google Scholar
  87. Hansen HH, Dombernowsky P, Hirsch FR, Hansen M, Rygärd J (1980) Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy. Cancer 46: 279–284PubMedCrossRefGoogle Scholar
  88. Hansen M, Hirsch F, Dombernowsky P, Hansen HH (1977) Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540,4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-ß-d-glucopyranoside). Cancer 40: 633–637PubMedCrossRefGoogle Scholar
  89. Hattori S, Matsuda M, Tateishi R, Nishihara H, Horai T (1972) Oat-cell carcinoma of the lung. Clinical and morphological studies in relation to its histogenesis. Cancer 30: 1014–1024PubMedCrossRefGoogle Scholar
  90. Havemann K, Gropp C (1980) Ektope Hormonproduktion beim kleinzelligen Bronchialkarzinom. Biologische und immunologische Aspekte. Internist 21: 84–94PubMedGoogle Scholar
  91. Havemann K, Harms V, Gropp C, Holle R, Victor N, Drings P, Manke HG, Bayer G, Dirks P, Georgii A, Mende S, Graubner M, Hans K, Heim M, Pfannschmidt G, Schroeder M, Thomas C, Wehr E, Weiß J, Mitrou PS, Diehl V (1984) Randomized trial comparing sequential combination chemotherapy with cyclic alternating chemotherapy in small cell lung cancer. Proc Am Soc Clin Oncol 3: 232 (C-908)Google Scholar
  92. Havsteen H, Sörenson S, Rørth M, Dombernowsky P, Hansen HH (1981) 5-Fu in the treatment of small cell anaplastic carcinoma of the lung: a phase II trial. Cancer Treat Rep 65: 123–125Google Scholar
  93. Heilmann H-P, Doppelfeld E, Fernholz H-J, Birkner R, Schlicker H, Becker G, Gordon-Harris L, Hackl A, Sager WD, Jentsch F, Kraft W, Bünemann H, Horstmann W, Hassenstein E, Kuttig H, Wieland C, Schmidt N, Müller A, Quäck J, Buchelt L, Heß F, Koop EA, Lieven H von, Heinze HG, Castrup W, Wannenmacher M, Rey G, Voss A-C, Nüse A, Eibach E, Grund W, Bohndorf W, Schindler G (1976) Ergebnisse der Strahlenbehandlung des Bron-chialkarzinoms. Dtsch Med Wochenschr 101: 1557–1562PubMedCrossRefGoogle Scholar
  94. Higgins GA (1972) Use of chemotherapy as an adjuvant to surgery for bronchogenic carcinoma. Cancer 30: 1383–1387PubMedCrossRefGoogle Scholar
  95. Higgins GA, Shields TW, Keehn RJ (1975) The solitary pulmonary nodule. Ten-year follow-up of Veterans Administration-Armed Forces cooperative study. Arch Surg 110: 570–575PubMedGoogle Scholar
  96. Hirsch FR, Matthews MJ, Yesner R (1982) Histopathologic classification of small cell carcinoma of the lung. Comments based on an interobserver examination. Cancer 50: 1360–1366PubMedCrossRefGoogle Scholar
  97. Hirsch FR, Østerlind K, Hansen HH (1983) The prognostic significance of histopathologic sub-typing of small cell carcinoma of the lung according to the classification of the World Health Organization. A study of 375 consecutive patients. Cancer 52: 2144–2150PubMedCrossRefGoogle Scholar
  98. Holoye PY, Libnoch JA, Byhardt RW, Cox JD (1982) Integration of chemotherapy and radiation therapy for small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 8: 1593–1596PubMedCrossRefGoogle Scholar
  99. Holsti LR, Mattson K (1980) A randomized study of split-course radiotherapy of lung cancer: long term results. Int J Radiat Oncol Biol Phys 6: 977–981PubMedCrossRefGoogle Scholar
  100. Horai T, Sone H, Takenaga A, Ikegami H, Matsuda M, Hattori S (1981) Cytologic characteristics of oatcell carcinoma of the lung in relation to the effect of chemotherapy. Cancer 47: 22–26PubMedCrossRefGoogle Scholar
  101. Høst H (1973) Cyclophosphamide (NSC-26271) as adjuvant to radiotherapy in the treatment of unresectable bronchogenic carcinoma. Cancer Chemother Rep part 3, 4 (2) 161–164Google Scholar
  102. Hyde L, Yee J, Wilson R, Patno ME (1965) Cell type and the natural history of lung cancer. J Am Med Assoc 193: 52–54Google Scholar
  103. Ihde DC, Cohen MH, Beraath AM, Matthews MJ, Bunn PA, Minna JD (1978) Serial fiberoptic bronchoscopy during chemotherapy for small cell carcinoma of the lung. Chest 74: 531–536PubMedCrossRefGoogle Scholar
  104. Ihde DC, Johnston-Early A, Carney DN, Cohen MH, Bunn PA, Pelsor FR, Minna DJ (1982) Lack of efficacy of high-dose methotrexate by 30-hour infusion in patients with progressive small cell carcinoma of the lung. Cancer Treat Rep 66: 1223–1225PubMedGoogle Scholar
  105. Ihde DC, Lichter AS, Deisseroth AB, Bunn PA, Carney DN, Cohen MH, Makuch RW, Johnston-Early A, Minna JD (1983) Late intensive combined modality therapy with autologous bone marrow infusion in extensive stage small cell lung cancer. 13th International Congress of Chemotherapy, Vienna. Proceedings, Vol 15, part 281, pp 5–8Google Scholar
  106. Ihde DC, Bunn PA, Lichter AS, Cohen MH, Makuch RW, Carney DN, Johnston-Early A, Minna JD, Glatstein E (1984) Randomized trial of chemotherapy with or without adjuvant chest irradiation in limited stage small cell lung cancer (SCLC). Abstracts - 4th International Conference on the Adjuvant Therapy of Cancer, Tucson, 36 (22)Google Scholar
  107. Jackson DV, Richards II F, Cooper R, Ferree C, Muss HB, White DR, Spurr CL (1977) Prophylactic cranial irradiation in small cell carcinoma of the lung. A randomized study. J Am Med Assoc 237: 2730–2733CrossRefGoogle Scholar
  108. Jackson D, Caponera M, Muss H, Rudnick S, Spurr C, Capizzi R (1984) Interferon alpha2 (rIFN-alpha2) in advanced small cell carcinoma of the lung. Proc Am Soc Clin Oncol 3: 226 (C-885)Google Scholar
  109. Johnson DH, Wolff SN, Hände KR, Hainsworth JD, Fer MF, Greco FA (1983) High-dose VP- 16-213 treatment of extensive small cell lung cancer. Proc Am Soc Clin Oncol 2: 193 (C- 754)Google Scholar
  110. Johnson DH, Hände KR, Marangos PJ, Forbes JT, Greco FA (1984) Serum neuron-specific enolase (NSE), a possible biomarker for small cell lung cancer. Proc Am Assoc Cancer Res 25: 156 (616)Google Scholar
  111. Johnson RE, Brereton HD, Kent CH (1976) Small-cell carcinoma of the lung: attempt to remedy causes of past therapeutic failure. Lancet 2: 289–291PubMedCrossRefGoogle Scholar
  112. Joss RA, Obrecht J-P, Jungi WF, Alberto P, Sauter C, Cavalli F (1984) Phase II study of vin- desine and hexamethylmelamine in patients with relapsing small cell carcinoma of the lung. Cancer Chemother Pharmacol 13: 148–149PubMedCrossRefGoogle Scholar
  113. Jungi WF, Senn HJ, Beckmann C, Flury R, Frei P, Holdener E (1975) Therapeutische Erfahrungen mit dem neuen Podophyllotoxinderivat VP 16-213 bei menschlichen malignen Tumoren. Schweiz Med Wochenschr 105: 1365–1369PubMedGoogle Scholar
  114. Karrer K, Denck H, Pridun N, Zwintz E, Coop. Group (1983) Combination of early surgery for cure and polychemotherapy in small-cell bronchial carcinoma. 13th International Congress of Chemotherapy, Vienna. Proceedings, Vol 11, part 228, pp 52–60Google Scholar
  115. Kato Y, Ferguson TB, Bennett DE, Burford TH (1969) Oat cell carcinoma of the lung. A review of 138 cases. Cancer 23: 517–524PubMedCrossRefGoogle Scholar
  116. Kessinger A, Foley JF, Lemon HM (1983) Therapeutic management of small cell lung cancer. Fewer toxic reactions with lower chemotherapeutic drug dosages. J Am Med Assoc 250: 3188–3191CrossRefGoogle Scholar
  117. Kies MS, Mira J, Chen T, Livingston RB (1982) Value of chest radiation in limited small cell lung cancer after chemotherapy-induced complete disease remission. Proc Am Soc Clin Oncol 1: 141 (C-546)Google Scholar
  118. Klastersky J, Sculier JP, Debusscher L, EORTC Lung Cancer Working Party (Belgium) (1983) Late intensification in small cell lung cancer. 13th International Congress of Chemotherapy, Vienna. Proceedings, Vol 15, part 281, pp 42–44Google Scholar
  119. Kokron O, Micksche M, Titscher R, Wrba H (1982) Ifosfamid versus Ifosfamid + CCNU in der Behandlung des inoperablen kleinzelligen Bronchuskarzinoms. Eine klinische Studie. Onkologie 5: 56–59PubMedCrossRefGoogle Scholar
  120. Komaki R, Cox JD, Whitson W (1981) Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. Cancer Treat Rep 65: 811–814PubMedGoogle Scholar
  121. Konrad RM, Ammedick U, Bläute R (1980) Soll das kleinzellige Bronchialkarzinom operiert werden? Med Welt 31: 1087–1091Google Scholar
  122. Kouteher J, Burt C, Teicher B, Brady T, Speak J, Bemal S (1984) Detection of small cell carcinoma with monoclonal antibody and fluorine NMR spectroscopy. Proc Am Assoc Cancer Res 25: 258 (1021)Google Scholar
  123. Krauss S, Macy S, Ichiki AT (1981) A study of immunoreactive calcitonin (CT), adrenocortico-tropic hormone (ACTH) and carcinoembryonic antigen (CEA) in lung cancer and other malignancies. Cancer 47: 2485–2492PubMedCrossRefGoogle Scholar
  124. Krischke W, Niederle N, Schütte J, Pfeiffer R, Seeber S, Schmidt CG (1984) Serial serum determinations of carcinoembryonic antigen (CEA) in small cell lung cancer: is there any clinical relevance? J Cancer Res Clin Oncol 107 [Suppl]: 34 (8/1 GA)Google Scholar
  125. Laing AH, Berry RJ, Newman CR, Smith P (1975) Treatment of small-cell carcinoma of bronchus. Lancet 1: 129–132PubMedCrossRefGoogle Scholar
  126. Lanzotti VJ, Thomas DR, Boyle LE, Smith TL, Gehan EA, Samuels ML (1977) Survival with inoperable lung cancer. An integration of prognostic variables based on simple clinical criteria. Cancer 39: 303–313PubMedCrossRefGoogle Scholar
  127. Lee JS, Lee YY, Umsawasdi T, Welch S, Kalter S, Farha P, Murphy WK, Valdivieso M (1984) Neurotoxicity in long term survivors of small cell lung cancer. Proc Am Soc Clin Oncol 3: 220 (C-859)Google Scholar
  128. Levenson RM Jr, Ihde DC, Huberman MS, Cohen MH, Bunn PA, Minna JD (1981) Phase II trial of cisplatin in small cell carcinoma of the lung. Cancer Treat Rep 65: 9–10Google Scholar
  129. Lininger TR, Fleming TR, Eagan RT (1981) Evaluation of alternating chemotherapy and sites and extent of disease in extensive small cell lung cancer. Cancer 48: 2147–2153PubMedCrossRefGoogle Scholar
  130. Livingston RB, Moore TN, Heilbrun L, Bottomley R, Lehane D, Rivkin SE, Thigpen T (1978) Small-cell carcinoma of the lung: combined chemotherapy and radiation. A. Southwest Oncology Group study. Ann Intern Med 88: 194–199PubMedGoogle Scholar
  131. Livingston RB, Stephens RL, Bonnet JD, Grozea PN, Lehane DE (1984) Long-term survival and toxicity in small cell lung cancer. Southwest Oncology Group Study. Am J Med 77: 415–417PubMedCrossRefGoogle Scholar
  132. Looper JD, Einhorn LH, Garcia SA, Hornback NB, Vincent B, Williams SD (1984) Severe neurologic problems following successful therapy for small cell lung cancer. Proc Am Soc Clin Oncol 3: 231 (C-903)Google Scholar
  133. Lowenbraun S, Bartolucci A, Smalley RV, Lynn M, Krauss S, Durant JD and the Southeastern Cancer Study Group (1979) The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 44: 406–413Google Scholar
  134. Matthews MJ (1983) Small cell carcinoma of the lung; influence of cell subtype in response to therapy. 13th International Congress of Chemotherapy, Vienna. Proceedings, Vol 11, part 228, pp 1–7Google Scholar
  135. Matthews MJ, Kanhouwa S, Pickren J, Robinette D (1973) Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep part 3,4(2): 63–67Google Scholar
  136. Mattson K, Niiranen A, Holsti LR, Andersson L, Grohn P, Cantell K (1982) High-dose human leukocyte interferon (IFN) as induction treatment for small cell lung cancer (SCLC). III. World Conference on Lung Cancer, Tokyo 1982, Abstracts, 161Google Scholar
  137. Mattson K, Holsti LR, Niiranen A, Pyrhönen S, Holsti P, Cantell K (1984) Maintenance interferon vs. maintenance chemotherapy following induction chemotherapy and consolidation radiotherapy in small cell lung cancer. Proc Am Soc Clin Oncol 3: 18 (C-185)Google Scholar
  138. Maubach PA, Holste R, Emmerich B, Ägilvie A, Präuer HW, Rastetter J (1984) Glycoprotein pattern of small-cell anaplastic carcinomas of the lung and their urinary excretion during chemotherapy. Blut 49: 229 (24)Google Scholar
  139. Maurer LH, Tulloh M, Weiss RB, Blom J, Leone L, Glidewell O, Pajak TF (1980) A randomized combined modality trial in small cell carcinoma of the lung: comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation. Cancer 45: 30–39PubMedCrossRefGoogle Scholar
  140. McKenzie CG, Evans IMA, Hillyard CJ, Hill P, Carter S, Tan MK, Maclntyre I (1977) Biochemical markers in bronchial carcinoma. Br J Cancer 36: 700–707PubMedCrossRefGoogle Scholar
  141. McMahon LD, Herman TS, Manning MR, Dean JC (1979) Patterns of relapse in patients with small cell carcinoma of the lung treated with adriamycin-cyclophosphamide chemotherapy and radiation therapy. Cancer Treat Rep 63: 359–362PubMedGoogle Scholar
  142. Medical Research Council (1979) Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung. Br J Cancer 40: 1–10Google Scholar
  143. Mehta C, Yogi SE (1982) Cycling non-cross resistant combination chemotherapy for small cell lung cancer in remission - 50% prolongation of remission duration without prolongation of survival and with enhanced toxicity. Proc Am Soc Clin Oncol 1: 152 (C-591)Google Scholar
  144. Meyer JA (1973) Growth rate versus prognosis in resected primary bronchogenic carcinomas. Cancer 31: 1468–1472PubMedCrossRefGoogle Scholar
  145. Meyer JA, Comis RL, Ginsberg SJ, Ikins PM, Burke WA, King GA, Gullo JJ, DiFino SM, Tinsley RW, Parker FB Jr (1982) Phase II trial of extended indications for resection in small cell carcinoma of the lung. J Thorac Cardiovasc Surg 83: 12–19PubMedGoogle Scholar
  146. Mira JG, Livingston RB, Moore TN, Chen T, Batley F, Bogardus CR Jr, Considine B Jr, Mansfield CM, Schlosser J, Seydel HG (1982) Influence of chest radiotherapy in frequency and patterns of chest relapse in disseminated small cell lung carcinoma. A Southwest Oncology Group Study. Cancer 50: 1266–1272PubMedCrossRefGoogle Scholar
  147. Mira JG, Kies MS, Chen T (1984) Influence of chest radiotherapy in response, remission duration, and survival in chemotherapy responders in localized small cell lung carcinoma: A Southwest Oncology Group Study. Proc Am Soc Clin Oncol 3: 212 (C-827)Google Scholar
  148. Morgan LR, Posey LE, Rainey J, Bickers J, Ryan D, Vial R, Hull EW (1981) Ifosfamide: a weekly dose fractionated schedule in bronchogenic carcinoma. Cancer Treat Rep 65: 693–695PubMedGoogle Scholar
  149. Mountain CF (1973) Keynote address on surgery in the therapy for lung cancer: surgical prospects and priorities for clinical research. Cancer Chemother Rep part 3, 4 (2): 19–24Google Scholar
  150. Mountain CF (1974) Surgical therapy in lung cancer: biologic, physiologic, and technical determinants. Semin Oncol 1: 253–258PubMedGoogle Scholar
  151. Muggia FM, Chervu LR (1974) Lung cancer: diagnosis in metastatic sites. Semin Oncol 1: 217–228PubMedGoogle Scholar
  152. Muggia FM, Krezoski SK, Hansen HH (1974) Cell kinetic studies in patients with small cell car-cinoma of the lung. Cancer 34: 1638–1690CrossRefGoogle Scholar
  153. Murray N, Hadzic E, Shah A, Band P, Voss N, Van den Hoek J, Murphy K, Sparling T, Noble M (1984) Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin for limited stage small cell carcinoma of the lung (SCCL). Proc Am Soc Clin Oncol 3: 214 (C- 835)Google Scholar
  154. Nakhosteen JA, Niederle N (1983) Small cell lung cancer. Serial bronchofiberscopy and photo-graphic documentation - the bridge sign. Chest 83: 12–16PubMedCrossRefGoogle Scholar
  155. Natale RB, Gralla RJ, Wittes RE (1981) Phase II trial of vindesine in patients with small cell lung carcinoma. Cancer Treat Rep 65: 129–131PubMedGoogle Scholar
  156. Neumann H, Fabricius H-A, Engelhard R (1982) Moderate whole-body hyperthermia in combination with chemotherapy in the treatment of small cell carcinoma of the lung: a pilot study. Natl Cancer Inst Monogr 61: 427–429Google Scholar
  157. Newman SJ, Hansen HH (1974) Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 33: 492–496PubMedCrossRefGoogle Scholar
  158. Niederle N (1984) Sogenannte prophylaktische Therapie von Hirnmetastasen. In: Heyden HW von, Krauseneck P (Hrsg) Hirnmetastasen. Pathophysiologic, Diagnostik und Therapie. Akt. Onkol 13. W. Zuckschwerdt Verlag, München Bern Wien, S 187–198Google Scholar
  159. Niederle N, Seeber S (1982) Zytostatische Behandlung der inoperablen und Nachbehandlung der operablen Bronchialkarzinome. Prax Pneumol 36: 305–311Google Scholar
  160. Niederle N, Krischke W, Schulz U, Schmidt CG, Seeber S (1982 a) Untersuchungen zur kurzzeitigen Induktions- und zyklischen Erhaltungstherapie beim inoperablen kleinzelligen Bronchialkarzinom. Klin Wochenschr 60: 829–838Google Scholar
  161. Niederle N, Krischke W, Bremer K, Schmidt CG, Seeber S (1982 b) Small-cell bronchogenic carcinoma - primary and relapse therapy with etoposide (VP-16), methotrexate and CCNU. Cancer Treat Rev [Suppl. A] 9: 101–105Google Scholar
  162. Niederle N, Nakhosteen JA, Maassen W, Seeber S (1983) Zur Bedeutung bronchofiberskopischer Therapiekontrollen beim inoperablen kleinzelligen Bronchialkarzinom. Prax Klin Pneumol 37: 859–861PubMedGoogle Scholar
  163. Niederle N, Schütte J, Schmidt CG, Seeber S (1984) Treatment of recurrent small cell lung carcinoma with vindesine and cisplatin. Cancer Treat Rep 68: 791–792PubMedGoogle Scholar
  164. Niederle N, Greschuchna D, Kasparek R, Schütte J, Schmidt CG (1985) Inoperable kleinzellige Bronchialkarzinome - Remissionskontrollen mittels Mediastinoskopie. Prax Klin Pneumol (im Druck )Google Scholar
  165. Nissen NI, Dombernowsky P, Hansen HH, Larsen Y (1976) Phase I clinical trial of an oral solution of VP-16-213. Cancer Chemother Rep 60: 943–945Google Scholar
  166. Nissen NI, Pajak TF, Leone LA, Bloomfield CD, Kennedy BJ, Ellison RR, Silver RT, Weiss RB, Cuttner J, Falkson G, Kung F, Bergevin PR, Holland JF (1980) Clinical trial of VP 16- 213 (NSC 141540) i.v. twice weekly in advanced neoplastic disease. A study by the Cancer and Leukemia Group B. Cancer 45: 232–235PubMedCrossRefGoogle Scholar
  167. Nõu E (1984) The natural five-year course in bronchial carcinoma. Epidemiologic results. Cancer 53: 2211–2216PubMedCrossRefGoogle Scholar
  168. Osieka R, Seeber S, Schmidt CG (1984) Predictive tests in cancer chemotherapy. A reappraisal. Klin Wochenschr 62: 203–212PubMedCrossRefGoogle Scholar
  169. Østerlind K, Dombernowsky P, Sørensen PG, Hansen HH (1981) Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma. Cancer Treat Rep 65: 245–248PubMedGoogle Scholar
  170. Østerlind K, Sörenson S, Hansen HH, Dombernowsky P, Hirsch FR, Hansen M, Rorth M (1983) Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res 43: 6085–6089PubMedGoogle Scholar
  171. Papac R, Bien R, Son Y, Kapp D, Yesner R (1984) Combined modality treatment of small cell lung cancer with cyclophosphamide, VP-16, methotrexate and high dose radiation. Proc Am Soc Clin Oncol 3: 216 (C-844)Google Scholar
  172. Pedersen AG, Sorenson S, Aabo K, Dombernowsky P, Hansen HH (1982) Phase II study of procarbazine in small cell carcinoma of the lung. Cancer Treat Rep 66: 273–275PubMedGoogle Scholar
  173. Perry MC, Eaton WL, Ware J, Zimmer B, Comis R, Chahinian AP, Skarin A, Carey R, Hirsh V (1984) Chemotherapy with or without radiation therapy in limited small cell cancer of the lung. Proc Am Soc Clin Oncol 3: 230 (C-901)Google Scholar
  174. Petrovich Z, Mietlowski W, Ohanian M, Cox J (1977) Clinical report on the treatment of locally advanced lung cancer. Cancer 40: 72–77PubMedCrossRefGoogle Scholar
  175. Pettengill OS, Sorenson GD, Wurster-Hill DH, Curphey TJ, Noll WW, Cate CC, Maurer LH (1980) Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung. Cancer 45: 906–918PubMedCrossRefGoogle Scholar
  176. Poplin EA, Aisner J, Van Echo DA, Whitacre M, Wiernik PH (1982) CCNU, vincristine, methotrexate, and procarbazine treatment of relapsed small cell lung carcinoma. Cancer Treat Rep 66: 1557–1559PubMedGoogle Scholar
  177. Poplin E, Whitacre M, Thompson B, Aisner J (1984) Small cell carcinoma of the lung: Influence of age on treatment outcome. Proc Am Soc Clin Oncol 3: 223 (C-871)Google Scholar
  178. Porter L, Johnson D, Hainsworth J, Grosh W, Wolff S, Hande K, Greco F (1984) Recurrent small cell lung carcinoma treated with VP-16 and cisplatinum. Proc Am Soc Clin Oncol 3: 215 (C-840)Google Scholar
  179. Posner JB, Chernik NL (1978) Intracranial metastases from systemic cancer. Adv Neurol 19: 575–587Google Scholar
  180. Radice PA, Matthews MJ, Ihde DC, Gazdar AF, Carney DN, Bunn PA, Cohen MH, Fossieck BE, Makuch RW, Minna JD (1982) The clinical behavior of “mixed” small cell/large cell bronchogenic carcinoma compared to “pure” small cell subtypes. Cancer 50: 2894–2902PubMedCrossRefGoogle Scholar
  181. Reddy SK, Takita H, Lane WW, Vincent RG, Chen TY, Caracandas JE, Regal A-M (1984) Cyclic alternating combination chemotherapy for small cell lung cancer. Cancer Chemother Pharmacol 12: 190–193PubMedCrossRefGoogle Scholar
  182. Richardson RL, Greco FA, Oldham RK, Liddle GW (1978) Tumor products and potential markers in small cell lung cancer. Semin Oncol 5: 253–262PubMedGoogle Scholar
  183. Rissanen PM, Tikka U, Holsti LR (1968) Autopsy findings in lung cancer treated with megavoltage radiotherapy. Acta Radiol Ther 7: 433–442Google Scholar
  184. Rosen ST, Makuch RW, Ihde DC, Matthews MJ, Minna JD, Glatstein E, Bunn PA Jr (1983) Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer. Am J Med 74: 615–624PubMedCrossRefGoogle Scholar
  185. Rosenfelt FP, Sikic BI, Daniels JR, Rosenbloom BE (1980) Phase II evaluation of cisdiamminedichloroplatinum (DDP) in small cell carcinoma of lung. Proc Am Assoc Cancer Res, Am Soc Clin Oncol 21: 449 (513)Google Scholar
  186. Rosenman J, Choi ND (1982) Improved quality of life of patients with small-cell carcinoma of the lung by elective irradiation of the brain. Int J Radiat Oncol Biol Phys 8: 1041–1043PubMedCrossRefGoogle Scholar
  187. Rushing DA, Baldauf MC, Gehisen JA, Kriesel DH, Koontz DP, Friedenberg WR (1984) High-dose BCNU and autologous bone marrow reinfusion in the treatment of refractory or relapse small cell carcinoma of the lung. Proc Am Soc Clin Oncol 3: 217 (C-846)Google Scholar
  188. Salazar OM, Rubin P, Brown JC, Feldstein ML, Keller BE (1976) Predictors of radiation response in lung cancer. A clinico-pathobiological analysis. Cancer 37: 2636–2650PubMedCrossRefGoogle Scholar
  189. Saugier B, Brunat M, Cordier JF, Gerard JP, Dorsit G, Marchandise JF, Bastidon R, Perol M, Brune J, Galy P (1978) Cancer pulmonaire á „petites cellules”. Résultats de l’association adriamycine-vincristine-cyclophosphamide chez 37 patients. Nouv Presse Méd 7: 1357–1361PubMedGoogle Scholar
  190. Schmoll HJ, Niederle N, Achterrath W (1981) Etoposid (VP 16-213). Eine antineoplastische Substanz aus der Reihe der Podophyllotoxine. Klin Wochenschr 59: 1177–1188PubMedCrossRefGoogle Scholar
  191. Schütte J, Niederle N, Krischke W, Seeber S, Schmidt CG (1984) Sequential alternating chemotherapy + radiotherapy in small cell lung cancer (SCLC). Proc Am Assoc Cancer Res 25: 177 (702)Google Scholar
  192. Sculier JP, Feld R, Evans WK, Shepherd FA, Payne DG, Pringle J, Yeoh JL, Quirt IC, Curtis JE, Myers R, Herman JG, De Boer G (1984 a) Neurological complications in patients with small cell lung cancer. Proc Am Soc Clin Oncol 3:222 (C-869)Google Scholar
  193. Sculier JP, Feld R, Evans WK, Shepherd FA, De Boer G, Malkin DG, Malkin A (1984 b) CEA: a useful prognostic marker for small cell lung cancer. Proc Am Assoc Cancer Res 25:158 (626)Google Scholar
  194. Seeber S (1980) Sensitivität und Resistenz bei der Tumortherapie. Verh Dtsch Ges Inn Med 86: 367–377PubMedGoogle Scholar
  195. Seeber S, Niederle N, Schilcher RB, Schmidt CG (1980) Adriamycin, Cyclophosphamid und Vincristin („ACO”) beim kleinzelligen Bronchialkarzinom. Verlaufsanalyse und Langzeitergebnisse. Onkologie 3: 5–11PubMedCrossRefGoogle Scholar
  196. Seeber S, Dimitriadis K, Schütte J, Schmidt CG (1984) Experimental basis and clinical experience with non-cross-resistant combinations in solid tumours. Cancer Treat Rev 11 [Suppl A]: 55–61PubMedCrossRefGoogle Scholar
  197. Shank B, Natale RB, Hilaris BS, Wittes RE (1981) Treatment of small cell carcinoma of lung with combined high dose mediastinal irradiation, whole brain prophylaxis and chemotherapy. Int J Radiat Oncol Biol Phys 7: 469–475PubMedCrossRefGoogle Scholar
  198. Shields TW, Matthews MJ, Higgins GA (1982 a) Long term adjuvant chemotherapy in patients after resection of carcinoma of the lung. Ill World Conference on Lung Cancer, Tokyo, Abstracts, 96(117)Google Scholar
  199. Shields TW, Higgins GA Jr, Matthews MJ, Keehn RJ (1982b) Surgical resection in the management of small cell carcinoma of the lung. J. Thorac Cardiovasc Surg 84: 481–488PubMedGoogle Scholar
  200. Sierocki JS, Hilaris BS, Hopfan S, Martini N, Barton D, Golbey RB, Wittes RE (1979) cis-Dichlorodiammineplatinum (II) and VP-16-213: an active induction regimen for small cell car-cinoma of the lung. Cancer Treat Rep 63: 1593–1597Google Scholar
  201. Slevin ML, Harvey VJ, Barnett MJ, Thompson J, Wood CD, Wrigley PFM (1984) Low dose, high frequency combination chemotherapy for extensive small cell lung carcinoma. Proc Am Soc Clin Oncol 3: 213 (C-833)Google Scholar
  202. Smith IE, Evans BD, Harland SJ (1983) High dose cyclophosphymide (7 g/m2) + autologous bone marrow rescue after conventional chemotherapy in patients with small cell lung cancer. Proc Am Soc Clin Oncol 2: 186 (C-726)Google Scholar
  203. Sörenson S (1983) Bronchoscopic findings in patients with a complete radiographic regression of small cell bronchogenic carcinoma. Eur J Cancer Clin Oncol 19: 589–595PubMedCrossRefGoogle Scholar
  204. Souhami RL, Harper PG, Linch D, Trask C, Goldstone AH, Tobias J, Spiro SG, Geddes DM, Richards JDM (1982) High-dose cyclophosphamide with autologous marrow transplantation as initial treatment of small cell carcinoma of the bronchus. Cancer Chemother Pharmacol 8: 31–34PubMedCrossRefGoogle Scholar
  205. Souhami RL, Geddes DM, Spiro SG, Harper PG, Tobias JS, Mantell BS, Fearon F, Bradbury I (1984) Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial. Br Med J 288: 1643–1646CrossRefGoogle Scholar
  206. Spitzer G, Farha P, Dicke K, Valdivieso M, Murphy W, Zander A, Chiuten D, Dhingra H, Jefferies D, Umsawasdi T (1984) High dose intensification with autologous bone marrow trans-plantation in limited small cell bronchogenic carcinoma. Proc Am Soc Clin Oncol 3: 211 (C- 864)Google Scholar
  207. Stahel RA, Takvorian RW, Skarin AT, Canellos GP (1984) Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. Eur J Cancer Clin Oncol 20: 1233–1238PubMedCrossRefGoogle Scholar
  208. Stevens E, Einhora L, Rohn R (1979) Treatment of limited small cell lung cancer. Proc Am Assoc Cancer Res, Am Soc Clin Oncol 20: 435 (C-599)Google Scholar
  209. Stewart P, Buckner CD, Thomas ED, Bagley C, Bensinger W, Gift RA, Appelbaum FR, Sanders J (1983) Intensive chemoradiotherapy with autologous marrow transplantation for small cell carcinoma of the lung. Cancer Treat Rep 67: 1055–1059PubMedGoogle Scholar
  210. Storm FK, Harrison WH, Elliott RS, Morton DL (1979) Normal tissue and solid tumor effects of hyperthermia in animal models and clinical trials. Cancer Res 39: 2245–2251PubMedGoogle Scholar
  211. Strauchen J A, Egbert BM, Kosek JC, Mackintosh R, Misfeldt DS (1983) Morphologic and clinical determinants of response to therapy in small cell carcinoma of the lung. Cancer 52: 1088–1092PubMedCrossRefGoogle Scholar
  212. Straus MJ (1974) The growth characteristics of lung cancer and its application to treatment design. Semin Oncol 1: 167–174PubMedGoogle Scholar
  213. Taetle R, Howell SB, Giuliani FC, Koziol J, Koessler A (1982) Comparison of the activity of doxorubicin analogues using colony-forming assays and human xenografts. Cancer 50: 1455–1461PubMedCrossRefGoogle Scholar
  214. Takita H, Brugarolas A, Marabella P, Vincent RG (1973) Small cell carcinoma of the lung. Clinicopathological studies. J Thorac Cardiovasc Surg 66: 472–477PubMedGoogle Scholar
  215. Tempero M, Foley JF, Kessinger A (1980) VP 16-213 after failure with combination chemotherapy for small cell carcinoma of the lung. Proc Am Assoc Cancer Res, Am Soc Clin Oncol 21: 460 (C-556)Google Scholar
  216. Thatcher N, Hunter RD, Jegarajah S, Barber PV, Carroll KB, Wilkinson PM, Crowther D (1982) 11-Week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for „limited”-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour Group. Lancet 1: 1040–1043Google Scholar
  217. Tong AW, Lee J, Stone MJ (1984) Diagnosis of human lung carcinoma cell types using a panel of monoclonal antibodies. Proc Am Assoc Cancer Res 25: 249 (985)Google Scholar
  218. Tosi P, Luzi P, Leoncini L, Miracco C, Gambacorta M, Grossi A (1981) Bronchogenic carcinoma: survival after surgical treatment according to stage, histologic type and immunomor-phologic changes in regional lymph nodes. Cancer 48: 2288–2295PubMedCrossRefGoogle Scholar
  219. Tucker RD, Sealy R, van Wyk C, le Roux PLM, Soskolne CL (1973) A clinical trial of cyclophosphamide (NSC-26271) and radiation therapy for oat cell carcinoma of the lung. Cancer Chemother Rep part 3, 4 (2): 159–160Google Scholar
  220. Tucker RD, Ferguson A, Van Wyk C, Sealy R, Hewitson R, Levin W (1978) Chemotherapy of small cell carcinoma of the lung with V.P. 16-213. Cancer 41: 1710–1714PubMedCrossRefGoogle Scholar
  221. Tucker WG, Radhakrishna V, Olayon Lo C, Lord RS (1978) Clinical experience with ifosfamide as a single agent and in combination with cis-platinum, 5-azacytidine, and BCNU in the treatment of lung cancer. In: Siegenthaler W, Liithy R (eds) Current chemotherapy. Proceedings of the 10th international congress of chemotherapy. American Society for Microbiology, Washington, DC 1074–1076Google Scholar
  222. Valdivieso M, Cabanillas F, Keating M, Barkley HT, Murphy WK, Brugess MA, Frazier H, Chen T, Bodey GP (1984a) Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units. Am J Med 76: 405–412PubMedCrossRefGoogle Scholar
  223. Valdivieso M, McMurtrey MJ, Farha P, Franzier OH, Spitzer G, Mountain CF (1984 b) Prospective evaluation of adjuvant surgical resection in small cell lung cancer. Proc Am Soc Clin Oncol 3:220 (C-858)Google Scholar
  224. Van Houtte P, Tancini G, de Jager R, Lustman-Marechal J, Milani F, Bonadonna G, Kenis Y (1979) Small cell carcinoma of the lung: a combined modality treatment. Eur J Cancer 15: 1159–1165Google Scholar
  225. Vincent RG, Wilson HE, Lane WW, Chen TY, Raza S, Gutierrez AC, Caracandas JE (1981) Progress in the chemotherapy of small cell carcinoma of the lung. Cancer 47: 229–235PubMedCrossRefGoogle Scholar
  226. Vogelzang NJ, Trowbridge RC, Frenning DH, Theologides A, Kennedy BJ, Kelly DR, Ewing SL, Vosika GJ (1980) Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine. Cancer Treat Rep 64: 997–1000PubMedGoogle Scholar
  227. Vollmer RT (1982) The effect of cell size on the pathologic diagnosis of small and large cell carcinomas of the lung. Cancer 50: 1380–1383PubMedCrossRefGoogle Scholar
  228. Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D, Makuch R (1981) Association between human tumor colony-forming assay results and response of an individual patient’s tumor to chemotherapy. Am J Med 70: 1027–1032CrossRefGoogle Scholar
  229. Waalkes TP, Abeloff MD, Woo KB, Ettinger DS, Ruddon RW, Aldenderfer R (1980) Carcinoembryonic antigen for monitoring patients with small cell carcinoma of the lung during treatment. Cancer Res 40: 4420–4427PubMedGoogle Scholar
  230. Waalkes TP, Abeloff MD, Ettinger DS, Woo KB, Kuo KC, Gehrke CW (1983) Serum protein-bound carbohydrates and small cell carcinoma of the lung. Correlations with extent of disease, tumor burden, survival, and clinical response categories. Cancer 52: 131–139PubMedCrossRefGoogle Scholar
  231. Watson WL, Berg JW (1962) Oat cell lung cancer. Cancer 15: 759–768PubMedCrossRefGoogle Scholar
  232. Weiss W (1974) Tumor doubling time and survival of men with bronchogenic carcinoma. Chest 65: 3–8PubMedCrossRefGoogle Scholar
  233. Weiss W, Boucot KR, Cooper DA (1970) The histopathology of bronchogenic carcinoma and its relation to growth rate, metastasis, and prognosis. Cancer 26: 965–970PubMedCrossRefGoogle Scholar
  234. Whang-Peng J, Kao-Shan CS, Lee EC, Bunn PA, Carney DN, Gazdar AF, Minna JD (1982) Specific chromosome defect associated with human small-cell lung cancer: Deletion 3p (14- 23). Science 215: 181–182PubMedCrossRefGoogle Scholar
  235. WHO (1983) The World Health Organization histological typing of lung tumors. Second edition. Am J Clin Pathol 77:123–136Google Scholar
  236. Woods RL, Levi JA (1984) Chemotherapy for small cell lung cancer: a randomised study of maintenance therapy with cyclophosphamide, adriamycin and vincristine (CAV) after remission induction with cisplatinum, VP 16-213 and radiotherapy. Proc Am Soc Clin Oncol 3: 214 (C-836)Google Scholar
  237. Young JA, Dillman RO, Seagren SL, Taetle R, Rentschler RE, Lea JW Jr, Lehar TJ, Green MR, Stanton W, Mendelsohn J, Royston I (1982) Non-cross-resistant chemotherapy and consolidation radiotherapy for small cell carcinoma of the lung. Cancer Treat Rep 66: 1399–1401PubMedGoogle Scholar
  238. Zelen M (1973) Keynote address on biostatistics and data retrieval. Cancer Chemother Rep part 3, 4 (2): 31–42Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • N. Niederle

There are no affiliations available

Personalised recommendations